Literature DB >> 11260324

Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.

S M Todryk1, L J Birchall, R Erlich, N Halanek, J K Orleans-Lindsay, A G Dalgleish.   

Abstract

Whole tumour cells are a logical basis for generating immunity against the cancers they comprise or represent. A number of human trials have been initiated using cytokine-transfected whole tumour cells of autologous (patient-derived) or allogeneic [major histocompatibility complex (MHC)-disparate] origin as vaccines. Although precedent exists for the efficacy of autologous-transfected cell vaccines in animal models, little preclinical evidence confirms that these findings will extrapolate to allogeneic-transfected cell vaccines. In order to address this issue a murine melanoma cell line (K1735) was transfected to secrete interleukin (IL)-2, IL-4, IL-7 or granulocyte-macrophage colony-stimulating factor (GM-CSF); cytokines currently in use in trials. The efficacy of these cells as irradiated vaccines was tested head-to-head in syngeneic (C3H) mice and in MHC-disparate (C57BL/6) mice, the former being subsequently challenged with K1735 cells and the latter with naturally cross-reactive B16-F10 melanoma cells. Whilst the GM-CSF-secreting vaccine was the most effective at generating protection in C3H mice, little enhancement in protection above the wild-type vaccine was seen with any of the transfections for the allogeneic vaccines, even though the wild-type vaccine was more effective than the autologous B16-F10 vaccine. Anti-tumour cytotoxic T-lymphocyte (CTL) activity was detected in both models but did not correlate well with protection, whilst in vitro anti-tumour interferon-gamma (IFN-gamma) secretion tended to be higher following the GM-CSF-secreting vaccine. Cytokine transfection of vaccines generally increased anti-tumour CTL activity and IFN-gamma secretion (T helper type 1 response). Further studies in other model systems are required to confirm this apparent lack of benefit of cytokine transduction over wild-type allogeneic vaccines, and to determine which in vitro assays will correlate best with protection in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260324      PMCID: PMC1783163          DOI: 10.1046/j.1365-2567.2001.01176.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

2.  The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.

Authors:  R Bannerji; C D Arroyo; C Cordon-Cardo; E Gilboa
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

3.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

4.  Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma.

Authors:  F Cavallo; F Di Pierro; M Giovarelli; A Gulino; A Vacca; A Stoppacciaro; M Forni; A Modesti; G Forni
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

5.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

Authors:  P T Golumbek; A J Lazenby; H I Levitsky; L M Jaffee; H Karasuyama; M Baker; D M Pardoll
Journal:  Science       Date:  1991-11-01       Impact factor: 47.728

6.  A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.

Authors:  E M Jaffee; R Abrams; J Cameron; R Donehower; M Duerr; J Gossett; T F Greten; L Grochow; R Hruban; S Kern; K D Lillemoe; S O'Reilly; D Pardoll; H A Pitt; P Sauter; C Weber; C Yeo
Journal:  Hum Gene Ther       Date:  1998-09-01       Impact factor: 5.695

7.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

Authors:  S E Townsend; J P Allison
Journal:  Science       Date:  1993-01-15       Impact factor: 47.728

8.  Immunotherapy of malignancy by in vivo gene transfer into tumors.

Authors:  G E Plautz; Z Y Yang; B Y Wu; X Gao; L Huang; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

9.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.

Authors:  A G Heriot; J B Marriott; S Cookson; D Kumar; A G Dalgleish
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more
  2 in total

Review 1.  Personalized dendritic cell-based tumor immunotherapy.

Authors:  Nona Janikashvili; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

2.  Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine.

Authors:  David G Casey; Joanne Lysaght; Tharappel James; Andrew Bateman; Alan A Melcher; Stephen M Todryk
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.